centrosomal protein 164 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored CEP164P1 profile across patient tissues and cancer cell-line models. CEP164P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CEP164P1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CEP164P1 RNA expression shows 16,458 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where CEP164P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP164P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP164P1 survival associations across molecular data types. CEP164P1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP164P1 RNA expression–survival associations across cancer types. High CEP164P1 expression shows unfavorable associations in UVM, COAD, LUAD, CESC and KIRC, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CEP164P1 RNA expression.
This table summarizes CEP164P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEP164P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP164P1 shows lower tumor expression in THCA, BRCA and LUAD and higher tumor expression in KIRC, COAD and BLCA. The THCA box plot shows higher CEP164P1 RNA expression in normal versus tumor tissue (log2 FC = −0.105, t-test p < 0.001).
This table shows molecular features associated with CEP164P1 in patient tissues and cancer cell lines. In patient samples, CEP164P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
